drugset / Trial / NCT01786382

A Drug Interaction Study of the Effects of PPI-668 on the Pharmacokinetics of Midazolam and Omeprazole

NCT01786382

Phase 1 Completed 24 enrolled Presidio Pharmaceuticals, Inc.
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The primary objectives of the study are to: * Evaluate the potential effects of PPI-668 at steady state on the pharmacokinetic (PK) profile of midazolam following a single oral dose in human subjects. * Evaluate the potential effects of PPI-668 at steady state on the PK profile of omeprazole following a single oral dose in human subject

Timeline

Start
2013-02
Primary completion
2013-03
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Midazolam Small molecule
Subject Omeprazole Other / unclassified
Subject Ravidasvir Small molecule
Subject Telaprevir Small molecule

Indications

No indication recorded.